Table 1.
Demographics and treatment characteristics in SJLIFE and CCSS
| Characteristics | SJLIFE | CCSS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Total (N=2,370, 100%) | Survivors with STC (N=65, 2.7%) | Survivors without STC (N=2,305, 97.3%) | Total (N=6,416, 100%) | Survivors with STC (N=121, 1.9%) | Survivors without STC (N=6,295, 98.1%) | |||||||
|
| ||||||||||||
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | |
| Age at diagnosis, years | ||||||||||||
| 0–4 | 922 | (38.9%) | 19 | (29.2%) | 903 | (39.2%) | 2,391 | (37.3%) | 30 | (24.8%) | 2,361 | (37.5%) |
| 5–9 | 538 | (22.7%) | 5 | (7.7%) | 533 | (23.1%) | 1,423 | (22.2%) | 21 | (17.4%) | 1,402 | (22.3%) |
| 10–14 | 532 | (22.4%) | 25 | (38.5%) | 507 | (22.0%) | 1,440 | (22.4%) | 47 | (38.8%) | 1,393 | (22.1%) |
| ≥15 | 378 | (15.9%) | 16 | (24.6%) | 362 | (15.7%) | 1,162 | (18.1%) | 23 | (19.0%) | 1,139 | (18.1%) |
| Sex | ||||||||||||
| Men | 1,265 | (53.4%) | 27 | (41.5%) | 1,238 | (53.7%) | 3,058 | (47.7%) | 41 | (33.9%) | 3,017 | (47.9%) |
| Women | 1,105 | (46.6%) | 38 | (58.5%) | 1,067 | (46.3%) | 3,358 | (52.3%) | 80 | (66.1%) | 3,278 | (52.1%) |
| Diagnosis | ||||||||||||
| Leukemia | 868 | (36.6%) | 19 | (29.2%) | 849 | (36.8%) | 1,713 | (26.7%) | 25 | (20.7%) | 1,688 | (26.8%) |
| Acute lymphoblastic leukemia | 802 | (33.8%) | 16 | (24.6%) | 786 | (34.1%) | 1,536 | (23.9%) | 21 | (17.4%) | 1,515 | (24.1%) |
| Acute myeloid leukemia | 63 | (2.7%) | 3 | (4.6%) | 60 | (2.6%) | 144 | (2.2%) | 1 | (0.8%) | 143 | (2.3%) |
| Other leukemia | 3 | (0.1%) | - | (0.0%) | 3 | (0.1%) | 33 | (0.5%) | 3 | (2.5%) | 30 | (0.5%) |
| CNS tumors | 249 | (10.5%) | 5 | (7.7%) | 244 | (10.6%) | 1,160 | (18.1%) | 19 | (15.7%) | 1,141 | (18.1%) |
| Astrocytoma or glioma | 123 | (5.2%) | - | (0.0%) | 123 | (5.3%) | 720 | (11.2%) | 5 | (4.1%) | 715 | (11.4%) |
| Medulloblastoma or PNET | 62 | (2.6%) | 4 | (6.2%) | 58 | (2.5%) | 271 | (4.2%) | 8 | (6.6%) | 263 | (4.2%) |
| Ependymoma | 25 | (1.1%) | 1 | (1.5%) | 24 | (1.0%) | ||||||
| Other CNS tumors | 39 | (1.6%) | - | (0.0%) | 39 | (1.7%) | 169 | (2.6%) | 6 | (5.0%) | 163 | (2.6%) |
| Lymphoma | 474 | (20.0%) | 32 | (49.2%) | 442 | (19.2%) | 1,373 | (21.4%) | 43 | (35.5%) | 1,330 | (21.1%) |
| Hodgkin lymphoma | 289 | (12.2%) | 30 | (46.2%) | 259 | (11.2%) | 849 | (13.2%) | 38 | (31.4%) | 811 | (12.9%) |
| Non-Hodgkin lymphoma | 185 | (7.8%) | 2 | (3.1%) | 183 | (7.9%) | 524 | (8.2%) | 5 | (4.1%) | 519 | (8.2%) |
| Sarcoma | 306 | (12.9%) | 3 | (4.6%) | 303 | (13.1%) | 1,028 | (16.0%) | 20 | (16.5%) | 1,008 | (16.0%) |
| Ewing sarcoma | 84 | (3.5%) | 2 | (3.1%) | 82 | (3.6%) | 194 | (3.0%) | 5 | (4.1%) | 189 | (3.0%) |
| Osteosarcoma | 82 | (3.5%) | - | (0.0%) | 82 | (3.6%) | 314 | (4.9%) | 10 | (8.3%) | 304 | (4.8%) |
| Rhabdomyosarcoma | 76 | (3.2%) | 1 | (1.5%) | 75 | (3.3%) | ||||||
| Non-rhabdomyosarcoma | 64 | (2.7%) | - | (0.0%) | 64 | (2.8%) | ||||||
| Soft tissue sarcoma | 520 | (8.1%) | 5 | (4.1%) | 515 | (8.2%) | ||||||
| Non-CNS Embryonal | 401 | (16.5%) | 5 | (7.7%) | 396 | (16.8%) | 1108 | (17.3%) | 12 | (9.9%) | 1096 | (17.4%) |
| Wilms tumor | 152 | (6.4%) | 1 | (1.5%) | 151 | (6.6%) | 621 | (9.7%) | 5 | (4.1%) | 616 | (9.8%) |
| Neuroblastoma | 119 | (5.0%) | 1 | (1.5%) | 118 | (5.1%) | 487 | (7.6%) | 7 | (5.8%) | 480 | (7.6%) |
| Germ cell tumor | 45 | (1.9%) | 1 | (1.5%) | 44 | (1.9%) | ||||||
| Retinoblastoma | 66 | (2.8%) | 2 | (3.1%) | 64 | (2.8%) | ||||||
| Hepatoblastoma | 16 | (0.7%) | - | (0.0%) | 16 | (0.7%) | ||||||
| Others | ||||||||||||
| Melanoma | 15 | (0.6%) | - | (0.0%) | 15 | (0.7%) | ||||||
| Carcinomas | 26 | (1.1%) | - | (0.0%) | 26 | (1.1%) | ||||||
| Other | 34 | (1.4%) | 1 | (1.5%) | 33 | (1.4%) | 34 | (0.5%) | 2 | (1.7%) | 32 | (0.5%) |
| Radiation therapy | ||||||||||||
| Neck-RT dose, Gy | ||||||||||||
| None | 1,894 | (79.9%) | 18 | (27.7%) | 1,876 | (81.4%) | 5,062 | (78.9%) | 48 | (39.7%) | 5,014 | (79.7%) |
| >0-<20 | 59 | (2.5%) | 6 | (9.2%) | 53 | (2.3%) | 175 | (2.7%) | 9 | (7.4%) | 166 | (2.6%) |
| ≥20-<30 | 247 | (10.4%) | 31 | (47.7%) | 216 | (9.4%) | 397 | (6.2%) | 28 | (23.1%) | 369 | (5.9%) |
| ≥30 | 170 | (7.2%) | 10 | (15.4%) | 160 | (6.9%) | 802 | (12.5%) | 36 | (29.8%) | 766 | (12.2%) |
| Chemotherapy | ||||||||||||
| Anthracycline dose, tertiles | ||||||||||||
| None | 988 | (41.7%) | 30 | (46.2%) | 958 | (41.6%) | 3,784 | (59.0%) | 72 | (59.5%) | 3,712 | (59.0%) |
| 1st tertile | 464 | (19.6%) | 2 | (3.1%) | 462 | (20.0%) | 361 | (5.6%) | 5 | (4.1%) | 356 | (5.7%) |
| 2nd tertile | 456 | (19.2%) | 19 | (29.2%) | 437 | (19.0%) | 937 | (14.6%) | 13 | (10.7%) | 924 | (14.7%) |
| 3rd tertile | 462 | (19.5%) | 14 | (21.5%) | 448 | (19.4%) | 1,334 | (20.8%) | 31 | (25.6%) | 1,303 | (20.7%) |
| Epipodophyllotoxin dose, tertiles | ||||||||||||
| None | 1,532 | (64.6%) | 43 | (66.2%) | 1,489 | (64.6%) | 5,693 | (88.7%) | 112 | (92.6%) | 5,581 | (88.7%) |
| 1st tertile | 271 | (11.4%) | 10 | (15.4%) | 261 | (11.3%) | 269 | (4.2%) | 2 | (1.7%) | 267 | (4.2%) |
| 2nd tertile | 282 | (11.9%) | 6 | (9.2%) | 276 | (12.0%) | 342 | (5.3%) | 6 | (5.0%) | 336 | (5.3%) |
| 3rd tertile | 285 | (12.0%) | 6 | (9.2%) | 279 | (12.1%) | 76 | (1.2%) | 1 | (0.8%) | 75 | (1.2%) |
| Treatment group | ||||||||||||
| Epipodophyllotoxin & Anthracycline 2–3 tertiles without neck-RT | 247 | (10.2%) | 7 | (10.8%) | 240 | (10.2%) | 392 | (6.1%) | 5 | (4.1%) | 387 | (6.1%) |
| Neck-RT >0-<20 Gy without Epipodophyllotoxin | 39 | (1.6%) | 3 | (4.6%) | 36 | (1.5%) | 132 | (2.1%) | 7 | (5.8%) | 125 | (2.0%) |
| Neck-RT ≥20-<30 Gy without Epipodophyllotoxin | 294 | (12.1%) | 22 | (33.8%) | 172 | (7.3%) | 360 | (5.6%) | 27 | (22.3%) | 333 | (5.3%) |
| Neck-RT ≥30 Gy without Epipodophyllotoxin | 135 | (5.6%) | 8 | (12.3%) | 127 | (5.4%) | 741 | (11.5%) | 36 | (29.8%) | 705 | (11.2%) |
| Neck-RT >0-<20 Gy with Epipodophyllotoxin | 20 | (0.8%) | 3 | (4.6%) | 17 | (0.7%) | 43 | (0.7%) | 2 | (1.7%) | 41 | (0.7%) |
| Neck-RT ≥20-<30 Gy with Epipodophyllotoxin | 53 | (2.2%) | 9 | (13.8%) | 44 | (1.9%) | 37 | (0.6%) | 1 | (0.8%) | 36 | (0.6%) |
| Neck-RT ≥30 Gy with Epipodophyllotoxin | 35 | (1.4%) | 2 | (3.1%) | 33 | (1.4%) | 41 | (0.6%) | - | (0.0%) | 41 | (0.7%) |
| None of the above | 1,647 | (67.9%) | 11 | (16.9%) | 1,636 | (69.3%) | 4,670 | (72.8%) | 43 | (35.5%) | 4,627 | (73.5%) |
| PRS | ||||||||||||
| 1st tertile | 791 | (33.4%) | 9 | (13.8%) | 782 | (33.9%) | 2,201 | (34.3%) | 22 | (18.2%) | 2,179 | (34.6%) |
| 2nd tertile | 789 | (33.3%) | 23 | (35.4%) | 766 | (33.2%) | 2,132 | (33.2%) | 40 | (33.1%) | 2,092 | (33.2%) |
| 3rd tertile | 790 | (33.3%) | 33 | (50.8%) | 757 | (32.8%) | 2,083 | (32.5%) | 59 | (48.8%) | 2,024 | (32.2%) |
|
| ||||||||||||
| Median | (IQR) | Median | (IQR) | Median | (IQR) | Median | (IQR) | Median | (IQR) | Median | (IQR) | |
|
| ||||||||||||
| Age at diagnosis, years | 7.1 | (3.1–13.1) | 12.0 | (4.2–14.9) | 6.9 | (3.1–13.1) | 7.5 | (3.3–13.6) | 11.1 | (5.0–14.3) | 7.4 | (3.2–13.6) |
| Age at follow-up, years | 36.6 | (30.3–44.1) | 42.2 | (37.7–48.6) | 36.5 | (30.1–43.9) | 36.5 | (30.2–44.2) | 42.6 | (36.7–49.3) | 36.4 | (30.1–44.1) |
| Length of follow-up, years | 28.8 | (21.9–36.1) | 31.6 | (26.7–37.9) | 28.8 | (21.9–36.1) | 28.9 | (22.6–34.6) | 32.5 | (25.7–38.4) | 28.8 | (22.5–34.5) |
Abbreviations: SJLIFE (St. Jude Lifetime cohort study), CCSS (Childhood Cancer Survivor Study), STC (subsequent thyroid cancer), CNS (central nervous system), PNET (primitive neuroectodermal tumor), RT (radiotherapy), PRS (polygenic risk score), IQR (interquartile range)